Sections
Revenue and Expenses 2019
Left to right: AACR CEO Margaret Foti, PhD, MD (hc); cancer survivors Eva Joseph, Tomma Hargraves, and Keith Taggart; AACR President Elaine R. Mardis, PhD, FAACR; and Tari A. King, MD, participated in a congressional briefing to launch the ninth annual AACR Cancer Progress Report. Advocacy efforts like this are a critical element of the AACR's mission.
In 2019, the AACR reported another year of positive operating returns. This financial stability enables the AACR to comprehensively meet the challenges of the cancer problem. Operating revenues totaled $97 million and total expenditures closely matched revenues. The net impact of revenues and expenses resulted in an operating surplus of $3 million. As outlined in this report, several major projects were launched in 2019, and the AACR was able to outperform the budget through successful programming, revenue growth, and prudent financial management.
Non-operating activities are primarily related to long-term investments. The AACR’s investments provided strong returns in the amount of $16.7 million in 2019 and outperformed comparable market indexes.
As a result of the financial performance for the year 2019, the AACR’s unrestricted net assets are now $91.8 million. These reserves ensure continued investment in the programs and initiatives that support the AACR’s mission to prevent and cure all cancers.
2019 TOTAL EXPENSES
2019 PROGRAM EXPENSES
American Association for Cancer Research, Inc. and the AACR Foundation
Unrestricted Revenues and Expenses (Unaudited)
As of December 31, 2019
| 2018 | 2019 | 2019 Percent of Total | ||||
| REVENUE | ||||||
| Membership Dues | $4,296,301 | $4,468,920 | 4% | |||
| Publications | $20,255,103 | $19,250,026 | 16% | |||
| Scientific Meetings and Educational Workshops | $25,709,669 | $27,275,031 | 22% | |||
| Other Revenue | $2,601,487 | $5,050,857 | 4% | |||
| Subtotal Program Revenue | $52,862,560 | $56,044,834 | 46% | |||
| Support | ||||||
| NIH Grants | $940,501 | $1,014,481 | 1% | |||
| Contributions | $59,743,733 | $65,906,634 | 54% | |||
| Subtotal Support Revenue | $60,684,234 | $66,921,115 | 54% | |||
| TOTAL REVENUE | $113,546,794 | $122,965,949 | 100% | |||
| EXPENSES | ||||||
| Research Grants and Scientific Awards | $52,983,961 | $57,505,643 | 48% | |||
| Scientific Meetings and Educational Workshops | $19,630,466 | $21,056,344 | 17% | |||
| Scientific Publications | $11,880,364 | $12,751,083 | 11% | |||
| Communications, Science Policy, and Patient Education | $8,256,107 | $8,437,727 | 7% | |||
| Professional Education and Scientific Programs | $5,646,414 | $7,846,974 | 7% | |||
| Subtotal Program Services | $98,397,312 | $107,597,771 | 89% | |||
| Member Services and Support Services | $8,687,678 | $7,902,730 | 7% | |||
| Fundraising and Development | $4,445,610 | $4,994,861 | 4% | |||
| Subtotal Supporting Services | $13,113,288 | $12,897,591 | 11% | |||
| TOTAL EXPENSES | $111,530,600 | $120,495,362 | 100% | |||
| Operating Surplus before Investments | $2,016,194 | $2,470,587 | ||||
| Investment Income | ($5,856,490) | $16,768,299 | ||||
| Change in Unrestricted Net Assets | ($3,840,296) | $19,238,885 | ||||
| NET ASSETS BEGINNING OF YEAR | $75,796,624 | $71,956,328 | ||||
| NET ASSETS END OF YEAR | $71,956,328 | $91,195,214 |
